Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients

被引：19
|
作者：
Negishi, Mayumi [1 ,2 ]
Shimomura, Kenju
Proks, Peter [3 ]
Shimomura, Yohnosuke [4 ]
Mori, Masatomo [2 ]
机构：
[1] Gunma Univ, Grad Sch Med, Heisei Hidaka Clin, Med Dept Diabet, Gunma 3700001, Japan
[2] Gunma Univ, Grad Sch Med, Dept Med & Mol Sci, Gunma 3700001, Japan
[3] Univ Oxford, HenryWellcome Ctr Gene Funct, Dept Physiol Anat & Genet, Oxford, England
[4] Gunma Prefectural Coll Hlth Sci, Gunma, Japan
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2008年 / 66卷 / 02期
关键词：
D O I：
10.1111/j.1365-2125.2008.03216.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：318 / 319
页数：2
相关论文
共 50 条
  • [21] Clinical evaluation of pioglitazone in patients with type 2 diabetes using α-glucosidase inhibitor and examination of its efficacy profile
    Hayashi, Y
    Miyachi, N
    Takeuchi, T
    Takeuchi, Y
    Kamiya, F
    Kato, T
    Imaeda, K
    Okayama, N
    Shimizu, M
    Itoh, M
    DIABETES OBESITY & METABOLISM, 2003, 5 (01): : 58 - 65
  • [22] Effects of pioglitazone or voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with type 2 diabetes
    Aso, Yoshimasa
    Yamamoto, Ruriko
    Suetsugu, Mariko
    Matsumoto, Sachiko
    Wakabayashi, Sadao
    Matsutomo, Rika
    Takebayashi, Kohzo
    Inukai, Toshihiko
    DIABETES, 2007, 56 : A87 - A87
  • [23] POSTPRANDIAL GLYCEMIC REDUCTION BY AN ALPHA-GLUCOSIDASE INHIBITOR IN TYPE-2 DIABETIC-PATIENTS WITH THERAPEUTICALLY ATTAINED BASAL NORMOGLYCEMIA
    HOLMAN, RR
    STEEMSON, J
    TURNER, RC
    DIABETES RESEARCH CLINICAL AND EXPERIMENTAL, 1991, 18 (04): : 149 - 153
  • [24] Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes
    Aso, Y.
    Yamamoto, R.
    Suetsugu, M.
    Matsumoto, S.
    Wakabayashi, S.
    Matsutomo, R.
    Takebayashi, K.
    Inukai, T.
    DIABETIC MEDICINE, 2007, 24 (09) : 962 - 968
  • [25] Association between Body Weight Gain from 20 Years of Age and Diabetic Nephropathy in Japanese Patients with Type 2 Diabetes
    Okada, Hiroshi
    Tanaka, Muhei
    Hasegawa, Goji
    Nakajima, Hanako
    Kadono, Mayuko
    Miyoshi, Tomoki
    Okada, Yuki
    Nakano, Koji
    Yamane, Tetsuro
    Fukui, Michiaki
    KIDNEY & BLOOD PRESSURE RESEARCH, 2019, 44 (04): : 583 - 589
  • [26] Composition of insulin-induced body weight gain in diabetic patients: A bio-impedance study
    Rigalleau, V
    Delafaye, C
    Baillet, L
    Vergnot, V
    Brunou, P
    Gatta, B
    Gin, H
    DIABETES & METABOLISM, 1999, 25 (04) : 321 - 328
  • [27] Increased body water content is the major cause of weight gain with pioglitazone despite improved hemodynamic parameters in type 2 diabetes
    Basu, A
    Rizza, RA
    Joyner, MJ
    Jensen, MD
    DIABETOLOGIA, 2005, 48 : A282 - A282
  • [28] Severe Acute Interstitial Nephritis Induced by α-glucosidase Inhibitor Miglitol in an Elderly Patient with Type 2 Diabetic Nephropathy
    Ono, Kazutoshi
    Masuda, Takahiro
    Ono, Yuko
    Hishida, Erika
    Yoshizawa, Hiromichi
    Imai, Toshimi
    Satonaka, Hiroshi
    Akimoto, Tetsu
    Nagata, Daisuke
    INTERNAL MEDICINE, 2024, 63 (20) : 2827 - 2831
  • [29] Genes associated with obesity, weight gain or insulin requirement in Japanese type 2 diabetic patients
    Nishi, M
    Sasahara, M
    Yabiku, K
    Furuta, H
    Hanabusa, T
    Sasaki, H
    Sanke, T
    Nanjo, K
    DIABETES, 2003, 52 : A559 - A559
  • [30] Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients
    Gastaldelli, Amalia
    Casolaro, Arturo
    Ciociaro, Demetrio
    Frascerra, Silvia
    Nannipieri, Monica
    Buzzigoli, Emma
    Ferrannini, Ele
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2009, 297 (01): : E225 - E230
12345